Home
NewsNewsLatest development marks a transformative step in endometriosis care by reducing diagnostic delays and enabling earlier treatment for improved patient outcomes. ENDOSURE's rapid and accurate diagnostic capability is expected to benefit thousands of women suffering from this chronic condition across Canada.
EndoDiagnosis has announced that CReATe Fertility is the first clinic in Canada to offer the innovative Tier 1 ENDOSURE diagnostic test for endometriosis, authorized by Health Canada since 2021. This non-invasive diagnostic test provides an accurate and rapid alternative to the traditional gold standard of laparoscopic surgery for diagnosing endometriosis, a chronic and often debilitating inflammatory disease affecting women globally.
The ENDOSURE test offers 99% accuracy, delivering results within 30 minutes during a single clinic visit without the need for referrals or laboratory processing. It detects all types and stages of endometriosis and is suitable for women of all ages, from pre-teens to post-menopausal individuals. This enables healthcare providers to quickly confirm endometriosis as the cause of menstrual or abdominal pain and infertility, which are common symptoms of the disease.
Endometriosis affects at least 10% of women worldwide, yet diagnosis is often delayed by 3 to 11 years due to the limitations and invasiveness of laparoscopy. Many patients endure prolonged suffering without accurate diagnosis because symptoms overlap with other conditions, and pain is sometimes dismissed by clinicians or attributed to normal menstrual discomfort. Tier 1 diagnostic testing like ENDOSURE addresses this diagnostic gap by providing a reliable, pain-free, and fast diagnostic option.
By incorporating ENDOSURE, CReATe Fertility is leading the way in Canadian reproductive healthcare to accelerate diagnosis and treatment. Early identification of endometriosis is critical as it allows for timely symptom management and interventions that can slow or stop disease progression and improve fertility outcomes. The ability to diagnose in real time also helps clinicians monitor patient responses post-treatment and adjust care plans accordingly.
The offering of the Tier 1 ENDOSURE test at CReATe Fertility empowers both patients and healthcare providers with a decision-support tool that transforms the experience of care. Patients gain faster access to answers, reducing years of uncertainty and enabling better quality of life. Clinicians receive actionable diagnostic data to guide personalized treatment pathways without the risks or costs associated with surgery.
This move is part of EndoDiagnosis’ broader mission to revolutionize endometriosis care worldwide by making rapid, accurate, and non-invasive diagnostics accessible. The company supports providers with education and a network to facilitate the adoption of ENDOSURE. With the introduction of this test in Canada, women suffering from chronic pelvic pain and infertility symptoms now have access to state-of-the-art diagnostics that validate their experiences and offer hope for better management.
Luna and Kindbody are redefining Intelligence in Fertility Care through a strategic partnership that integrates wearable biomarker tracking into clinical pathways. By capturing real-time physiological data, the collaboration enables personalised insights, enhances decision-making, and creates a more connected, data-driven fertility journey for patients and care providers alike.
Sapyen and Avenues launch at-home fertility diagnostics, introducing a couple-first testing model in the UK. By integrating semen analysis and AMH testing into early care, this approach reduces clinic visits, accelerates diagnosis, and ensures balanced fertility evaluation, transforming how patients begin their reproductive health journey.
Nexpring Health has invested in May Health to accelerate the development of the Anavi™ System, a novel device designed to treat PCOS-Related Infertility. The technology aims to restore ovulation through a single office-based procedure, expanding treatment options for millions of women affected by polycystic ovary syndrome.
INVO Fertility would be introducing time-lapse incubation technology at its Wisconsin clinic, hence offering high-quality lab care, creative patient solutions, and advanced embryo monitoring for improved fertility results.
Costco, Sesame, and IVI RMA North America have announced strategic partnership to alter fertility care in the U.S. by removing biggest obstacles to care including high costs and limited access.
Carea has launched its Trying to Conceive - IVF/IUI mode to help women undergoing intricate fertility treatment with risks of inconsistent clinic continuity through continuous tracking and expert guidance.
The Minnesota bill for infertility treatments mandates comprehensive insurance coverage for diagnosis, IVF, and fertility preservation across public and private health plans. Set for implementation in 2027, the legislation expands access, modernises infertility definitions, and ensures cost-sharing protections to make reproductive healthcare more equitable.
